Skip to content

Comparison of Venlafaxine and Bupropion on depression of Bipolar II disorder

Comparison of effect of Venlafaxin and Bupropion in treatment of Depressive episode of Bipolar II disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200913048698N1
Enrollment
60
Registered
2020-12-12
Start date
2020-12-10
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar II disorder. Bipolar II disorder

Interventions

Intervention 1: Intervention group: This group receives 75 mg Bupropion tablets made in Iran equivalent to 75 mg every morning and re-evaluated by Hamilton Depression Inventory two weeks, three weeks

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of Depressive episode of Bipolar II disorder according to DSM V Ability to take oral medication informed consent from the patient or parents The patient has not used another antidepressant within four weeks of starting the drug

Exclusion criteria

Exclusion criteria: Sucidal tought Psychosis The current episode is mixed Rapid cycling Dyspepsia or peptic ulcer Pregnant and lactating women Intellectual disabilitie History of alcohol and substance abuse up to six months before the start of the project The patient's depression is caused by a physical illness using drugs or medication Existence of any severe and chronic physical illness, cerebrovascular disease, seizures or history of substance use Psychotic depression

Design outcomes

Primary

MeasureTime frame
Depression Score Hamilton Questionnaire. Timepoint: Depression score of Hamilton questionnaire is calculated before intervention, and 14, 21 and 28 days after intervention. Method of measurement: Hamilton Questionnaire.

Secondary

MeasureTime frame
Hypo mania score with MDQ questionnaire. Timepoint: Before starting the intervention. Method of measurement: MDQ Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhatere Asadi

Ahvaz University of Medical Sciences

dr.kh.asadi@gmail.com+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026